Market News

Aurinia Pharmaceuticals Inc. (AUPH) Reaches $5.20 After 9.00% Down Move; MEDOVEX (MDVX) SI Decreased By 62.6%

Medovex Corporation (OTCMKTS:MDVX) Logo

MEDOVEX CORP (OTCMKTS:MDVX) had a decrease of 62.6% in short interest. MDVX’s SI was 34,000 shares in April as released by FINRA. Its down 62.6% from 90,900 shares previously. With 39,100 avg volume, 1 days are for MEDOVEX CORP (OTCMKTS:MDVX)’s short sellers to cover MDVX’s short positions. The SI to MEDOVEX CORP’s float is 0.27%. It closed at $0.455 lastly. It is down 69.11% since April 5, 2017 and is downtrending. It has underperformed by 80.66% the S&P500.

The stock of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a huge mover today! The stock decreased 1.61% or $0.09 during the last trading session, reaching $5.2. About 75,605 shares traded. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has declined 33.20% since April 5, 2017 and is downtrending. It has underperformed by 44.75% the S&P500.The move comes after 8 months negative chart setup for the $434.85M company. It was reported on Apr, 5 by Barchart.com. We have $4.73 PT which if reached, will make NASDAQ:AUPH worth $39.14 million less.

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company has market cap of $434.85 million. The firm is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It currently has negative earnings. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc.

Among 6 analysts covering Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aurinia Pharmaceuticals Inc had 14 analyst reports since June 30, 2016 according to SRatingsIntel. The stock of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) earned “Buy” rating by H.C. Wainwright on Friday, December 30. The firm has “Buy” rating given on Thursday, March 15 by Cantor Fitzgerald. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, June 5. As per Tuesday, October 24, the company rating was maintained by Canaccord Genuity. The rating was maintained by Leerink Swann with “Outperform” on Monday, October 23. On Thursday, June 30 the stock rating was initiated by H.C. Wainwright with “Buy”. Seaport Global maintained Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) on Friday, March 16 with “Buy” rating. The firm has “Speculative Buy” rating by Canaccord Genuity given on Wednesday, September 13. The stock of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) earned “Buy” rating by Cantor Fitzgerald on Monday, October 23. The stock has “Buy” rating by Cantor Fitzgerald on Friday, August 11.

MedoveX Corporation, through its subsidiaries, focuses on developing medical devices primarily in the United States and Europe. The company has market cap of $9.98 million. It offers DenerveX device, a disposable single-use kit for the treatment of various medical applications, including pain relief. It currently has negative earnings. The firm serves healthcare providers, physicians, and third-party payors.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *